Serum haptoglobin, CA 125 and interleukin 6 levels in malignant and non-malignant tumors of the ovary

Archivum Immunologiae et Therapiae Experimentalis

Volumn 47, Issue 4, 1999, Pages 229-236

  Dobryszycka, Wanda ^a   Katnik Prastowska, Iwona ^a   Gerber, Jerzy ^a   Lemańska, Krystyna ^a   Utko, Krystyna ^a   Rozdolski, Krzysztof ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

CA 125; Haptoglobin concanavalin A; Haptoglobin hemoglobin; Interleukin 6; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; HAPTOGLOBIN; INTERLEUKIN 6; TUMOR MARKER;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; OVARY TUMOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; HAPTOGLOBINS; HUMANS; INTERLEUKIN-6; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032601945     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. BAST R. C., FEENEY M., LAZARUS H., NADLER L. M., CALVIN R. B. and KNAPP R. C. (1981): Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest., 68, 1331-1337.
2. BAUMANN H. and GAULDIE J. (1994): The acute phase response. Immunol. Today, 15, 74-80.
3. BEREK J. S. and BAST R. C. (1995): Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer, 76, 2092-2096.
4. BEREK J. S., CHUNG C., KALDI K., WATSON J. M., KNOX R. M. and MARTINEZ-MAZA O. (1991): Serum interleukin 6 levels correlate with disease status in patients with epithelial ovarian cancer. Am. J. Obstet. Gynecol., 164, 1038-1043.
5. BEZWODA W. R. (1986): Treatment of advanced ovarian cancer: a randomized trial comparing Adriamycin or 4'-epiadriamycin in combination with cis-platin and cyclophosphamide. Med. Pediatr. Oncol., 14, 26-29.
6. BON G. G., KENEMANS P., VERSTRAETEN R., VAN KAMP G. J. and HILGERS J. (1996): Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am. J. Obstet. Gynecol., 174, 107-114.
7. CASWELL M., PIKE L. A., BULL B. S. and STUART J. (1993): Effect of patient age on tests of the acute-phase response. Arch. Pathol. Lab. Med., 117, 906-910.
8. DE GRAAF T. W., SLOT S. S., PETERS G. J. and VAN DIJK W. (1993): Changes in glycosylation of L1210 cells after exposure to various antimetabolites. Eur. J. Cancer, 29A, 1760-1765.
9. DEVINE P. L., MCGUCKIN M. A., QUIN R. J. and WARD B. G. (1995): Predictive value of the combination of serum markers, CA 125, CASA and TPS in ovarian cancer. Int. J. Gynecol. Cancer, 5, 170-178.
10. DOBRYSZYCKA W. (1997): Biological functions of haptoglobin. New pieces to an old puzzle. Eur. J. Clin. Chem. Clin. Biochem., 35, 647-654.
11. DOBRYSZYCKA W., GERBER J., ZUWAŁA-JAGIEŁŁO J. and UJEC M. (1991): Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma. Arch. Immunol. Ther.Exp., 39, 41-50.
12. DROEGEMUELLI R W. (1994): Screening for ovarian carcinoma: hopeful and wishful thinking. Am. J. Obstet. Gynecol., 170, 1095-1098.
13. ECKHARDT S., SZANTO J., CERAR O., CHYLAK V., HERNADI Z., HINDY I. et al (1987): Activity of Epirubicin in combination chemotherapy of advanced ovarian cancer. Oncology, 44, 1-4.
14. EINHORN N., KNAPP R. C., BAST R. C. and ZURAVSKI V. R. JR. (1989): CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and nonmalignant diseases of the ovary. Acta Oncol., 28, 655-657.
15. EMERICH J., DUDZIAK M., CIEŚLAK D. and KOBIERSKI J. (1993): Ocena porównawcza przydatności klinicznej oznaczeń haptoglobiny i antygenu CA 125 u kobiet leezonych z powodu raka jajnika. Nowotwory, 43, 164-169.
16. FRASCI G., CONFORTI S., ZULLO F., MASTRANTONIO P., COMELLA G., COMELLA P., PERSICO G. and IAFFAIOLI R. V. (1996): A risk model for ovarian carcinoma patients using CA 125. Cancer, 77, 1122-1130.
17. GASTL G., PLANTE M., FINSTAD C. L., WONG G. Y., FEDERICI M. G., BANDER N. H. and RUBIN S. C. (1993): High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br. J. Haematol., 83, 433-441.
18. HARŁOZIŃSKA A., SEDLACZEK P., VAN DALEN A., ROZDOLSKI K. and EINARSSON R. (1997): TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms. Anticancer Res., 17, 4473-4478.
19. HASHOLZNER U., BAUMGARTNER L., STIEBER P., MEIER W., REITER W., PAHL H. and FATCH-MOGHADAM A. (1996): Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma. Int. J. Cancer, 69, 329-334.
20. HENDRICKSON T. L., SPENCER J. R., KATO M. and IMPERIALI B. (1996): Design and evaluation of potent inhibitors of asparagine-linked protein glycosylalion. J. Am. Chem. Soc., 115, 7636-7637.
21. HIRANO T. (1992): Interleukin 6 and autoimmunity and plasma cell neoplasias. Clin. Immunol. Immunopathol., 62, 759-763.
22. JONES G. E. and MOULD D. L. (1984): Adaptation of the guaiacol (peroxidase) test for haptoglobins to a microtitrtion plate system. Res. Vet. Sci., 37, 87-92.
23. KATNIK I. and DOBRYSZYCKA W. (1992): Development of concanavalin A-enzyme immunosorbent assay for glycated haptoglobin using polyclonal and monoclonal antibodies. J. Immunoassay, 13, 145-162.
24. KATNIK I. and JADACH J. (1996): Haptoglobin concentration in serum and other body fluids measured by comparison of its reactivity with hemoglobin and concanavalin A. Arch. Immunol. Ther. Exp., 44, 45-50.
25. KATNIK I., JADACH J., KMIECIAK K., GERBER J. and DOBRYSZYCKA W. (1995): Measurements of haptoglobin by the reaction with concanavalin A in sera of patients with ovarian tumors. J. Clin. Chem. Clin. Biochem., 33, 727-732.
26. KIM Y. J. and WARKI A. (1997): Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconjugates, 14, 569-576.
27. KOTTMEIER H. L. (1971): Report presented by the cancer committee to the General Assembly of FIGO. Int. J. Gynecol. Obstet., 9, 178.
28. MADEWELL B. R. (1997): Tumor markers. In KANEKO J. J. and HARVEY J. W. (eds.): Clinical biochemistry of domestic animals. Academic Press, San Diego, USA, 761-784.
29. NAGELE F., PETRU E., MEDL M., KAINZ C., GRAF A. H. and SEVELDA P. (1995): Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet. Gynecol., 86, 259-264.
30. NARAYANAN S. (1996): Laboratory markers as an index of aging. A. Clin. Lab. Sci., 26, 50-59.
31. OKA Y., MURATA A., NISHIJIMA J., YASUDA T., HIRAOKA N., OBMACHI Y., KITAGAWA K., YASUDA T., TODA H., TANAKA N. and MORI T. (1992): Circulating interleukin 6 as a useful marker for predicting postoperative complications. Cytokine, 4, 298-304.
32. ONSRUD M., SHABANA A. and AUSTGULERS R. (1996): Soluble tumor necrosis factor and CA 125 in serum as markers for epithelial ovarian cancer. Tumor Biol., 17, 90-96.
33. PLANTE M., RUBIN S. C., WONG G. Y., FEDERICI M. G., FINSTAD C. L. and GASTL L. A. (1994): Interleukin 6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer, 73, 1882-1888.
34. RIEDINGER J. M., BARILLOT I., COUDERT B., FARGEOT P. and BERRIOLO-RIEDINGER A. (1996): Valeur prognostique de la demi-vie initiale du CA 125 mesuree au cours de la chimiotherapie d'induction chez 62 patientes porteuses de tumeur epitheliale ovarienne stade III ou IV. Bull. Cancer, 83, 654-663.
35. SCHWARTZ P. E. and TAYLOR K. J. W. (1995): Is early detection of ovarian cancer possible? Ann. Med., 27, 519-528.
36. SHABANA A. and ONSRUD M. (1994): Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma. Tumor Biol., 15, 361-367.
37. SURESH M. R. (1996): Classification of tumor markers. Anti-cancer Res., 16, 2273-2278.
38. TILG H., DINARELLO C. A. and MIER J. W. (1997): IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol. Today, 18, 428-432.
39. VAN DIJK W., TURNER G. A. and MACKIEWICZ A. (1994): Changes in glycosylation of acute phase proteins in health and disease: occurence, regulation and function. Glycosylation Dis., 1, 15-19.
40. WARWAS M., DOBRYSZYCKA W., GERBER J. and PIETKIEWICZ A. (1981): Clinical usefulness of serum acute phase reactants in patients with ovarian tumors. Neoplasma, 28, 485-490.
41. WARWAS M., GERBER J. and PIETKIEWICZ A. (1986): Haptoglobin and proteinase inhibitors in the blood serum of women with inflammatory, benign and neoplastic lesions of the ovary. Neoplasma, 33, 79-84.
42. WARWAS M., HACZYŃSKA H. GERBER J. and NOWAK M. (1997): Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma. Eur. J. Clin. Chem. Clin. Biochem., 35, 301-304.